Screener
Stoke Therapeutics, Inc. STOK Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $155,659 | $84,220 |
| Marketable securities - current | 187,886 | 200,450 |
| Accounts receivable | 4,451 | 5,936 |
| Prepaid expenses | 10,115 | 8,736 |
| Interest receivable | 1,690 | 1,969 |
| Other current assets | 6,880 | 4,389 |
| Total current assets | $366,681 | $305,700 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s accounts receivable?
- Stoke Therapeutics, Inc. (STOK) reported accounts receivable of $4.45M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s accounts receivable changed year-over-year?
- Stoke Therapeutics, Inc.'s accounts receivable increased by 235.9% year-over-year, from $1.33M to $4.45M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Stoke Therapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude